Shet Anita, Nagaraja Pradeep, Dixit Narendra M
*Department of Pediatrics, Division of Infectious Diseases, St. John's Medical College Hospital, Bangalore, India; †Department of Chemical Engineering, Indian Institute of Science, Bangalore, India; and ‡Centre for Biosystems Science and Engineering, Indian Institute of Science, Bangalore, India.
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):245-251. doi: 10.1097/QAI.0000000000001101.
Despite the high prevalence of HIV-1 subtype C (HIV-1C) worldwide, information on HIV-1C viral dynamics and response to antiretroviral therapy (ART) is limited. We sought to measure viral load decay dynamics during treatment and estimate the within-host basic reproductive ratio, R0, and the critical efficacy, εc, for successful treatment of HIV-1C infection.
Individuals initiated on first-line ART in India and monitored for 6 months of treatment were considered. Viral load, CD4 count, and adherence data were collected at baseline, 4, 12, 16 and 24 weeks after ART initiation. Drug resistance genotyping was performed at baseline. R0 and εc were estimated using a mathematical model.
Among 257 patients with complete data, mean baseline viral load was 5.7 log10 copies per milliliter and median CD4 count was 165 cells per cubic millimeter. Primary drug resistance was present in 3.1% at baseline. At 6 months, 87.5% had undetectable viral load, indicating excellent response to ART despite high baseline viremia. After excluding those with transmitted resistance, suboptimal adherence and viral rebound, data from 112 patients were analyzed using a mathematical model. We estimated the median R0 to be 5.3. The corresponding εc was ∼0.8.
These estimates of R0 and εc are smaller than current estimates for HIV-1B, suggesting that HIV-1C exhibits lower in vivo fitness compared with HIV-1B, which allows successful treatment despite high baseline viral loads. The lower fitness, and potentially lower virulence, together with high viral loads may underlie the heightened transmission potential of HIV-1C and its growing global spread.
尽管HIV-1 C亚型(HIV-1C)在全球广泛流行,但关于HIV-1C病毒动力学及对抗逆转录病毒疗法(ART)反应的信息有限。我们试图测量治疗期间病毒载量的衰减动力学,并估计成功治疗HIV-1C感染的宿主内基本繁殖数R0和临界疗效εc。
纳入在印度开始一线ART治疗并接受6个月治疗监测的个体。在ART开始时的基线、4周、12周、16周和24周收集病毒载量、CD4细胞计数和依从性数据。在基线时进行耐药基因分型。使用数学模型估计R0和εc。
在257例有完整数据的患者中,平均基线病毒载量为每毫升5.7 log10拷贝,CD4细胞计数中位数为每立方毫米165个细胞。基线时原发耐药率为3.1%。6个月时,87.5%的患者病毒载量不可检测,表明尽管基线病毒血症水平高,但对ART反应良好。排除有传播性耐药、依从性欠佳和病毒反弹的患者后,使用数学模型分析了112例患者的数据。我们估计R0中位数为5.3。相应的εc约为0.8。
这些R0和εc的估计值小于目前对HIV-1B的估计值,表明与HIV-1B相比,HIV-1C在体内的适应性较低,这使得尽管基线病毒载量高仍能成功治疗。较低的适应性以及可能较低的毒力,再加上高病毒载量,可能是HIV-1C传播潜力增加及其在全球范围内不断蔓延的原因。